Guowei Fang
Chief Tech/Sci/R&D Officer bij LEGEND BIOTECH CORPORATION
Profiel
Guo Wei Fang is currently the Chief Scientific Officer at Legend Biotech Corp.
Prior to this, he held the position of Head-Discovery at Pharmacyclics LLC and Senior Vice President-Research at Zymeworks BC, Inc. He completed his undergraduate degree at Nanjing University and obtained his doctorate from the University of Colorado Boulder.
Actieve functies van Guowei Fang
Bedrijven | Functie | Begin |
---|---|---|
LEGEND BIOTECH CORPORATION | Chief Tech/Sci/R&D Officer | 01-03-2022 |
Eerdere bekende functies van Guowei Fang
Bedrijven | Functie | Einde |
---|---|---|
PHARMACYCLICS, INC. | Corporate Officer/Principal | - |
Zymeworks BC, Inc.
Zymeworks BC, Inc. BiotechnologyHealth Technology Zymeworks BC, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of biotherapeutics. Its product, ZW25 and ZW49, are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada. | Chief Tech/Sci/R&D Officer | - |
Opleiding van Guowei Fang
Nanjing University | Undergraduate Degree |
University of Colorado Boulder | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
LEGEND BIOTECH CORPORATION | Health Technology |
Bedrijven in privébezit | 2 |
---|---|
Pharmacyclics LLC
Pharmacyclics LLC Pharmaceuticals: MajorHealth Technology Pharmacyclics LLC engages in developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. It has product candidates in clinical development and several preclinical molecules in optimization. The company was founded by Jonathan Sessler and Richard Miller in 1991 and is headquartered in Sunnyvale, CA. | Health Technology |
Zymeworks BC, Inc.
Zymeworks BC, Inc. BiotechnologyHealth Technology Zymeworks BC, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of biotherapeutics. Its product, ZW25 and ZW49, are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada. | Health Technology |